


The validation of the Revised International Staging System (R-ISS) in an independent cohort of patients with multiple myeloma confirms it as a robust tool for risk stratification of newly diagnosed patients with symptomatic myeloma



R-ISS could identify three groups with distinct outcomes

	%	5-year survival rate (p<0.001)
R-ISS-1	18%	77%
R-ISS-2	64.5%	53%
R-ISS-3	17.5%	19%

The identification was possible among patients

- treated with or without autologous stem cell transplantation
- treated with either bortezomib based or IMiD-based primary therapy
- ≤65, 66-75 or >75 years

In patients with severe renal dysfunction the distinction between groups was less clear